key: cord-0858608-8duszuy9
authors: Wu, Di; Shu, Ting; Yang, Xiaobo; Song, Jian-Xin; Zhang, Mingliang; Yao, Chengye; Liu, Wen; Huang, Muhan; Yu, Yuan; Yang, Qingyu; Zhu, Tingju; Xu, Jiqian; Mu, Jingfang; Wang, Yaxin; Wang, Hong; Tang, Tang; Ren, Yujie; Wu, Yongran; Lin, Shu-Hai; Qiu, Yang; Zhang, Ding-Yu; Shang, You; Zhou, Xi
title: Plasma Metabolomic and Lipidomic Alterations Associated with COVID-19
date: 2020-04-28
journal: Natl Sci Rev
DOI: 10.1093/nsr/nwaa086
sha: d11d48835b131be1803f1f9bd09ce0a2b5a8a6e4
doc_id: 858608
cord_uid: 8duszuy9

The pandemic of the coronavirus disease 2019 (COVID-19) has become a global public health crisis. The symptoms of COVID-19 range from mild to severe conditions. However, the physiological changes associated with COVID-19 are barely understood. In this study, we performed targeted metabolomic and lipidomic analyses of plasma from a cohort of COVID-19 patients who had experienced different symptoms. We found the metabolite and lipid alterations exhibit apparent correlation with the course of disease in these COVID-19 patients, indicating that the development of COVID-19 affected whole-body metabolism of the patients. In particular, malic acid of the TCA cycle and carbamoyl phosphate of urea cycle reveal the altered energy metabolism and hepatic dysfunction, respectively. It should be noted that carbamoyl phosphate is profoundly down-regulated in fatal patients compared with mild patients. And more importantly, guanosine monophosphate (GMP), which is mediated by not only GMP synthase but also CD39 and CD73, is significantly changed between healthy subjects and COVID-19 patients, as well as between the mild and fatal groups. In addition, the dyslipidaemia was observed in COVID-19 patients. Overall, the disturbed metabolic patterns have been found to align with the progress and severity of COVID-19. This work provides valuable knowledge about plasma biomarkers associated with COVID-19 and potential therapeutic targets, as well as important resource for further studies of COVID-19 pathogenesis.

The outbreak of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been declared a pandemic by the World Health in some developed countries probably due to a more elderly population (2).

The main attacking organ of SARS-CoV-2 is low respiratory tract, and some patients develop life-threatening acute respiratory distress syndrome (ARDS). Besides, the attacks of liver, muscle, gastrointestinal tract, lymph node, and heart by SARS-CoV-2 have also been found or proposed (3) (4) (5) (6) . On the other hand, although more than 80% COVID-19 patients experienced only mild symptoms, it has been found that the conditions can rapidly progress from mild to severe ones, particularly in the absence of adequate medical care. Moreover, the mortality rate of COVID-19 in critically ill cases can be over 60%, posing great pressure on treatment (7) . However, the physiological changes associated with COVID-19 under different symptomatic conditions are barely understood.

Metabolites and lipids are major molecular constituents in human plasma. During critical illness, metabolic and lipid abnormalities are commonly observed, which are believed to contribute to physiology and pathology. Moreover, previous studies have demonstrated dramatic alterations of metabolome and lipidome in human plasma caused by various diseases including viral infections, like Ebola virus disease (8, 9) .

Here, we performed the targeted metabolomic and lipidomic profiles of plasma samples collected from a cohort of COVID-19 patients, including COVID-19 fatalities and survivors recovered from mild or severe symptoms. Our findings here show many of the metabolite and lipid alterations, particularly ones associated with hepatic functions, align with the progress and severity of the disease, which would provide valuable knowledge about plasma biomarkers associated with COVID-19 as well as potential therapeutic targets, and shed light on the pathogenesis of COVID-19.

Blood samples were harvested at Wuhan Jinyintan Hospital from COVID-19 patients who were confirmed by laboratory nucleic acid test of SARS-CoV-2 infection. Serial samples were collected over the course of disease from 9 patients with fatal (F) outcome (F1-F4), 11 patients diagnosed as severe (S) symptoms (S1-S2), and 14 patients diagnosed as mild (M) symptoms (M1-M2) (Table S1 ). Of note, all the patients in the severe (S) and mild (M) groups had survived from COVID-19 and been discharged from the hospital. F1 represents the first samples collected from the COVID-19 fatal patients, while F4 represents the last samples before additional samples could be collected. S1 or M1 represents the samples during the disease peak of the patients in the severe or mild group as being determined based on the Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (6th edition) published by the National Health Commission of China (10), while S2 or M2 represents the last samples collected from patients in each group before the patients were discharged from the hospital. For comparison, the blood samples from 10 healthy volunteers, whose throat swabs and serological testing were negative for SARS-CoV-2, were collected. The hydrophilic and hydrophobic metabolites were extracted from each plasma sample, respectively and measured by employing liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) system. The metabolite identification was conducted by home-made database with retention time and ion pairs. For those metabolites without authentic standards in our database, we still used MS/MS spectra to search against the public databases for improving the confidence of metabolite identification. The orthogonal partial least-squares discriminant analysis (OPLS-DA) was used to discriminate metabolomic profiles between the groups of COVID-19 patients and healthy people (Figure S1-S4). In total, 431 metabolites and 698 lipids were identified and quantified, and both metabolome and lipidome showed dramatic alterations in the plasma of these COVID-19 patients (Table S2 and S3).

For different courses of fatal COVID-19 patients (F1-F4), we analyzed the metabolites that underwent significant change [F4 vs. H, >1 log 2 fold change (FC) <-1, typically P <0.05]. For F vs. H, 87 of the total 431 metabolites were significantly different (P < 0.05) at F1, while the number of significantly altered metabolites increased to 162 at F4 in the fatalities; and most of the changes are down-regulated (Table S2) . We found a positive correlation between the alteration of metabolites and the course of disease deterioration in fatal patients ( Figure 1A and Table S4 ), indicating that the development of disease affects the metabolism of metabolites.

We also profiled the metabolites in the different courses of severe and mild COVID-19 patients (S1 and S2; M1 and M2), and analyzed those that underwent the significant change [S1 vs. H, >1 log 2 FC <-1, typically P <0.05; M1 vs. H, >1 log 2 FC <-1, typically P <0.05] ( Figure 1B and Table S5 ). There are apparently less metabolites with significant changes (>1 log 2 FC <-1, typically P <0.05) observed in severe and mild patient groups when compared with those of fatal patients, and almost all the significantly altered metabolites were down-regulated. These results indicate that the alterations of metabolic pathways were more extensive in fatal COVID-19 cases than in severe and mild ones who finally survived.

In addition, it is noteworthy that although the patients in both severe and mild groups had met the hospital discharge criteria in the time points S2 and M2 as their COVID-19 nucleic acid tests which turn out to be negative twice consecutively, our metabolomic data clearly show that many of their metabolites had not returned to normal levels when compared with those in healthy volunteers ( Figure 1B ), suggesting that these discharged patients had not been fully recovered from the impacts of COVID-19 in physiology.

To further analyze the metabolomic data, the differentiating metabolites were (Table S4 and Table S5 ). Thereby, we postulate that a deficiency of malic acid and aspartate due, at least in part, to SARS-CoV-2 replication by hijacking nucleic acids from host cells, because the TCA cycle and aspartate would be preferent for purine and pyrimide nucleotide biosynthesis. One more differentiating metabolite guanosine monophosphate (GMP) is also observed, which involved the metabolic reactions mediated by not only GMP synthase but also CD39 and CD73. Both CD39 and CD73 are the immunomodulatory enzymes, suggesting that CD39/CD73 axis imbalance may occur in COVID-19

patients. In addition, we observed that the level of carbamoyl phosphate was significantly and gradually reduced over the course of COVID-19 fatalities.

Carbamoyl phosphate is synthesized from free amino donors by carbamoyl phosphate synthetase I (CPSI) in mitochondria of liver cells, and participates in the urea cycle to remove excess ammonia and produce urea (14) (15) (16) (17) . Its reduction in fatal cases of COVID-19 suggests the possibility of liver damage, which could also impair amino acid and pyrimidine metabolisms since CPSI could also maintain pyrimidine pool.

Notably, both GMP and carbamoyl phosphate show significant changes between fatal and mild patients, indicating that the disease progression is associated with immune dysfunction and nucleotide metabolism.

We We observed that phosphatidylcholines (PCs) were gradually reduced over the course of COVID-19 fatalities. We also analyzed the lipids in different courses of severe and mild COVID-19 patients (S1 and S2; M1 and M2) that underwent the significant change [S1 vs. H, >1 log 2 FC <-1, typically P <0.05; M1 vs. H, >1 log 2 FC <-1, typically P <0.05] ( Figure 4B and Table S9 ). Similar to those of metabolites, the total numbers of significantly altered lipids (>1 log 2 fold change (FC) <-1, typically P Table S11 ).

To highlight the top differentiating lipids, we showed 8 down-regulated lipids and 7 up-regulated lipids in COVID-19 patients compared with those in the healthy group ( Figure 6 and Table S12 ), suggesting the dyslipidaemia in COVID-19 patients.

To rule out the possibility of potential biomarkers induced by age difference and/or gender disparity, we developed a logistic regression model for COVID-19 patients and healthy controls. As shown in Table 1 , odds ratio (OR) for age is 0.95, indicating that age does not significantly affect the five key plasma metabolites as shown in Figure 3 . Although OR for gender is 3.67, the P-value is higher than 0.05, indicating that gender is not strongly associated with the metabolite panel. Therefore, either age or gender is not markedly contributed to the plasma metabolite panel highlighted by comparing COVID-19 with healthy controls.

Next, we generated ROC curves to assess the potential usefulness of plasma Intriguingly, ROC curve analysis of glycerol 3-phosphate with an AUC value of 1.00 was observed, suggesting that circulating glycerol 3-phosphate would be a good biomarker for COVID-19. These obtained results suggest metabolomics and lipidomics provide a potential tool for disease diagnosis and drug targets in the current pandemic.

The main purposes of this study were to generate a high-quality resource of metabolomic and lipidomic datasets associated with COVID-19 and identify the potential biomarkers for disease diagnosis for a better understanding of the pathogenesis of COVID-19.

Among the highlighted biomarkers, malic acid and glycerol 3-phosphate showed the greatest reduction when comparing the fatality patients with healthy volunteers, and also showed dramatic reduction in both severe and mild groups. Malic acid has important physiological functions, as it can directly enter the circulation of TCA cycle to participate in human energy metabolism. Besides, malic acid can accelerate ammonia transformation to lower ammonia concentration in liver and to protect liver (23, 24) . Therefore, the dramatic reduction of malic acid is consistent with the hepatic impairment associated with COVID-19. Moreover, malic acid has been found to protect endothelial cells of human blood vessels and resist damage to endothelial cells.

Xu-5-P is a metabolite of the pentose phosphate pathway that mediates the effects of carbohydrate feeding on the glycolytic pathway, as well as fatty acid and triglyceride synthesis. Xu-5-P is the coordinating signal that both activates phosphofructokinase in glycolysis and promotes transcription of the genes for lipogenesis, the hexose monophosphate shunt, and glycolysis, and is required for de novo synthesis of fat and hepatic energy utilization (25) (26) (27) (28) . The reduction of Xu-5-P suggests that altered glucose and lipid metabolisms are also a reflection of hepatic impairment.

removing excess ammonia in the urea cycle (14, 15) . This metabolite is the downstream product of CPSI in mitochondria of liver cells. The observed down-regulation of carbamoyl phosphate levels is associated with the severity of COVID-19, as its level in the mild patients were affected in the least extent.

Importantly, the dramatic reduction of carbamoyl phosphate is usually associated with urea cycle disorder, raising the concern about the possibility of hyperammonemia and liver failure in COVID-19 patients. The postulation seems to be consistent with deficiency of malic acid as mentioned above. In addition, the metabolisms of purine and thyroid hormones were significantly altered in the fatality group. Purine metabolism mainly occurs in human liver, and the thyroid hormone can affect hepatic protein synthesis and glycogen decomposition. Therefore, our findings imply that the development of COVID-19 may cause hepatic impairment in these patients, which is consistent with the observations that a large number of COVID-19 patients showed liver function abnormalities (Table S13 ) (6) .

Besides, the reductions of dihydrouracil, an intermediate breakdown product of uracil and guanosine monophosphate (GMP) (29) , are proposed to be caused by the defects of human metabolism. It should be noted that GMP production is not only mediated by GMP synthase but also CD39 and CD73. Indeed, CD39/CD73 axis plays a crucial role in immunity and inflammation (30) . Meanwhile, the lipids involved in glycerol metabolism pathway were upregulated, which maintain the balance of the energy metabolites of the body and are beneficial to the energy required for viral replication, suggesting that SARS-CoV-2

probably hijacks cellular metabolism like many other viruses (33) . Our data show that the metabolic pathway of glycerophospholipids has been significantly changed, and glycerophospholipids are closely related with cardiovascular diseases. However, we did not find obvious pattern or significant difference of underlying diseases, such as hypertension, cardiac disease, diabetes, cerebrovascular disease, chronic hepatitis, and cancer, in the medical records of all the patient groups involved in this study.

Therefore, this finding suggests that the fatality caused by COVID-19 might be related with cardiac impairment. Interestingly, COVID-19 has been recently reported to probably cause the loss of the smell and taste sense (34) , and the KEGG analysis also showed that the taste transduction pathway is affected.

The metabolomic and lipidomic analyses also show that, although the patients in both the severe and mild symptom groups had met the official hospital discharge criteria as their COVID-19 nucleic acid tests for turning out to be negative consecutively twice and major clinical signs disappeared, many of their fundamental metabolites and lipids failed to return to normal at the time when they were discharged. This finding suggests that these discharged patients, regardless of the severity of their previous symptoms, had not been fully recovered from the disease in the aspect of metabolism. Therefore, even after the clearance of SARS-CoV-2 from patient bodies, these convalescent COVID-19 patients still need better nutrition and care that would be very helpful for their faster and full recovery from the aftermath of the disease. 

Materials and methods are detailed described in Supplementary data.

Supplementary Figure 

The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) -China

Clinical Characteristics of 138 Hospitalized Patients With

Novel Coronavirus-Infected Pneumonia in Wuhan

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Liver injury in COVID-19: management and challenges

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. The Lancet Respiratory Medicine

Multi-platform 'Omics Analysis of Human Ebola Virus Disease Pathogenesis

Plasma lipidome reveals critical illness and recovery from human Ebola virus disease

National Health Commission of China, T. National Health Commission of China. New coronavirus pneumonia prevention and control program

Have we enough glutamine and how does it work? A clinician's view

Plasma Hypoxanthine-Guanine Phosphoribosyl Transferase Activity in Bottlenose Dolphins Contributes to Avoiding Accumulation of Non-recyclable Purines

Determination of Activity of the Enzymes Hypoxanthine Phosphoribosyl Transferase (HPRT) and Adenine Phosphoribosyl Transferase (APRT) in Blood Spots on Filter Paper

Nuclear localization and mitogen-activated protein kinase phosphorylation of the multifunctional protein CAD

Release of the mitochondrial enzyme carbamoyl phosphate synthase under septic conditions

Subcutaneous and intrahepatic growth of human hepatoblastoma in immunodeficient mice

Transcriptional repression of human cad gene by hypoxia inducible factor-1alpha

Phosphatidylcholine biosynthesis and lipoprotein metabolism

Serum metabolome and lipidome changes in adult patients with primary dengue infection

Mortality prediction in patients with severe septic shock: a pilot study using a target metabolomics approach

Impact of serial measurements of lysophosphatidylcholine on 28-day mortality prediction in patients admitted to the intensive care unit with severe sepsis or septic shock

Plasma lyso-phosphatidylcholine concentration is decreased in cancer patients with weight loss and activated inflammatory status

Microbial biosynthesis and secretion of l-malic acid and its applications

Effect of Malate-oligosaccharide Solution on Antioxidant Capacity of Endurance Athletes

A humble hexose monophosphate pathway metabolite regulates short-and long-term control of lipogenesis

Characterization of enzymatic D-xylulose 5-phosphate synthesis

Dynamic simulation of red blood cell metabolism and its application to the analysis of a pathological condition

Xylulose 5-phosphate mediates glucose-induced lipogenesis by xylulose 5-phosphate-activated protein phosphatase in rat liver

The impact of liver resection on the dihydrouracil:uracil plasma ratio in patients with colorectal liver metastases

CD39 and CD73 in immunity and inflammation

Glycerol-3-phosphate cytidylyltransferase

Glycerol-3-phosphate is a critical mobile inducer of systemic immunity in plants

Viral hijacking of cellular metabolism

Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms

We thank the patients, and the nurses and clinical staffs who are providing care for these patients. We thank the helpful discussions with Drs. Yan Wang and Yong Liu at Wuhan University. We also thank many staff members at Wuhan Jinyintan Hospital and Wuhan Metware Biotechnology Co., Ltd. for their contributions and assistance in this study. We sincerely pay tribute to our colleagues who have strived in the forefront of taking care of COVID-19 patients and are studying this novel coronavirus in Wuhan and other places around the world. 

The authors declare no conflicts of interest.